Related Experiment Video
Updated: Jan 14, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
9.5K
Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles.
Silvia Mutti1,2, Alessia Cavalleri1,2, Stefania Federici3,4
1Department of Clinical and Experimental Sciences, University of Brescia, Unit of Blood Diseases and Bone Marrow Transplant, ASST Spedali Civili, Brescia, Italy.
Journal of Cellular and Molecular Medicine
|October 22, 2025
Summary
Extracellular vesicles (EVs) from different Chronic Myeloid Leukaemia (CML) models show distinct characteristics and responses to Tyrosine Kinase Inhibitors (TKIs). This highlights the importance of preclinical model selection for CML research.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chronic Myeloid Leukaemia (CML) is driven by the BCR::ABL1 fusion gene.
- Tyrosine Kinase Inhibitors (TKIs) have improved CML treatment, but drug resistance and disease persistence necessitate better preclinical models.
- Extracellular Vesicles (EVs) are implicated in leukaemia progression, carrying oncogenic cargo like BCR::ABL1.
Purpose of the Study:
- To investigate whether EVs derived from different CML cell lines exhibit distinct features and cargo.
- To assess the impact of TKI treatment on EV release and BCR::ABL1 content in CML models.
- To explore the relationship between EV characteristics, TKI response, and cellular proliferation markers.
Main Methods:
- Characterization of EVs from K562 and KCL22 CML cell lines using Fourier Transform Infrared (FTIR) spectroscopy, Atomic Force Microscopy (AFM), dot blotting, and Nanoparticle Tracking Analysis (NTA).
- Quantification of EV release and BCR::ABL1 transcript levels before and after treatment with imatinib, nilotinib, or dasatinib.
- Assessment of Ki67 expression as a proliferation marker.
Main Results:
- FTIR with Principal Component Analysis (PCA) demonstrated distinct clustering of EVs based on the originating cell line.
- While basal EV output and BCR::ABL1 content were similar, post-TKI treatment, K562 cells released more EVs with increased BCR::ABL1 transcripts.
- KCL22 cells exhibited an earlier decrease in Ki67 expression following TKI treatment compared to K562 cells.
Conclusions:
- EV behavior in CML models is cell line-dependent, reflecting the heterogeneity observed in CML patients.
- These findings underscore the critical need for careful selection of preclinical models in CML research to accurately represent disease biology and treatment responses.
- Understanding model-specific EV dynamics is crucial for developing targeted therapies and overcoming TKI resistance.
